Allorion Therapeutics raises $50M for precision medicine in oncology and autoimmune diseases
Summary
Upholding a science- and data-driven R&D strategy, we will continue to fully leverage our teams capabilities, platforms, and funds to advance clinical development and address unmet medical needs for patients. We look forward to the clinical data of its leading assets and believe that the companys platforms will continue to generate highly innovative pre-clinical candidates to address significant unmet medical needs and serve patients around the world. The team has advanced two molecules to the clinical stage and verified the companys allosteric inhibitor and synthetic lethality screening platforms, demonstrating its strong execution capability. We are very much looking forward to the clinical data, additional high-quality drug candidates generated by the companys technology platforms, and its collaboration with international and Chinese pharma, driving more innovations valuable to human health. "Wei Cheng, Managing Director of TF Capital, commented, "Its very impressive that Allorion built a strong team with global competitiveness in just two and a half years.
Funding
Review available funding amount, funding date, investors, and linked company information related to Allorion Therapeutics raises $50M for precision medicine in oncology and autoimmune diseases in the interactive ISVWorld profile.
Classifications
AskAI Classifications
LabelsLinked Companies
